Endovascular Ultrasound Renal Denervation to Treat Hypertension
JAMA · 28.02.2023 · 329 (8) · 651
DOI: 10.1001/jama.2023.0713 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA, erschienen am 28.02.2023. Verfasst von Michel Azizi und 25 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, Paris, France. Hauptthemen laut MEDLINE: Denervation, Hypertension, Ultrasonography, Interventional. Die Arbeit wurde bisher 201-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust.
Abstract (Originalsprache)
Importance Two initial sham-controlled trials demonstrated that ultrasound renal denervation decreases blood pressure (BP) in patients with mild to moderate hypertension and hypertension that is resistant to treatment.
Objective
To study the efficacy and safety of ultrasound renal denervation without the confounding influence of antihypertensive medications in patients with hypertension. Design, Setting, and Participants Sham-controlled, randomized clinical trial with patients and outcome assessors blinded to treatment assignment that was conducted between January 14, 2019, and March 25, 2022, at 37 centers in the US and 24 centers in Europe, with randomization stratified by center. Patients aged 18 years to 75 years with hypertension (seated office systolic BP [SBP] ≥140 mm Hg and diastolic BP [DBP] ≥90 mm Hg despite taking up to 2 antihypertensive medications) were eligible if they had an ambulatory SBP/DBP of 135/85 mm Hg or greater and an SBP/DBP less than 170/105 mm Hg after a 4-week washout of their medications. Patients with an estimated glomerular filtration rate of 40 mL/min/1.73 m 2 or greater and with suitable renal artery anatomy were randomized 2:1 to undergo ultrasound renal denervation or a sham procedure. Patients were to abstain from antihypertensive medications until the 2-month follow-up unless prespecified BP criteria were exceeded and were associated with clinical symptoms.
Interventions
Ultrasound renal denervation vs a sham procedure. Main Outcomes and Measures The primary efficacy outcome was the mean change in daytime ambulatory SBP at 2 months. The primary safety composite outcome of major adverse events included death, kidney failure, and major embolic, vascular, cardiovascular, cerebrovascular, and hypertensive events at 30 days and renal artery stenosis greater than 70% detected at 6 months. The secondary outcomes included mean change in 24-hour ambulatory SBP, home SBP, office SBP, and all DBP parameters at 2 months.
Results
Among 1038 eligible patients, 150 were randomized to ultrasound renal denervation and 74 to a sham procedure (mean age, 55 years [SD, 9.3 years]; 28.6% female; and 16.1% self-identified as Black or African American). The reduction in daytime ambulatory SBP was greater with ultrasound renal denervation (mean, −7.9 mm Hg [SD, 11.6 mm Hg]) vs the sham procedure (mean, −1.8 mm Hg [SD, 9.5 mm Hg]) (baseline-adjusted between-group difference, −6.3 mm Hg [95% CI, −9.3 to −3.2 mm Hg], P < .001), with a consistent effect of ultrasound renal denervation throughout the 24-hour circadian cycle. Among 7 secondary BP outcomes, 6 were significantly improved with ultrasound renal denervation vs the sham procedure. No major adverse events were reported in either group. Conclusions and Relevance In patients with hypertension, ultrasound renal denervation reduced daytime ambulatory SBP at 2 months in the absence of antihypertensive medications vs a sham procedure without postprocedural major adverse events. Trial Registration ClinicalTrials.gov Identifier: NCT03614260
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Université Paris Cité, Paris, France.
- AP-HP, Hôpital Européen Georges-Pompidou, Hypertension Department and DMU CARTE, Paris, France.
- INSERM, CIC1418, Paris, France.
- Barts NIHR Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, London, England.
- Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, Minnesota.
- Ochsner Medical Center, New Orleans, Louisiana.
Förderung
- Wellcome Trust
Zitieren
APA
Azizi, M., Saxena, M., Wang, Y., Jenkins, J. S., Devireddy, C., Rader, F., Fisher, N. D. L., Schmieder, R. E., Mahfoud, F., Lindsey, J., Sanghvi, K., Todoran, T. M., Pacella, J., Flack, J., Daemen, J., Sharp, A. S. P., Lurz, P., Bloch, M. J., Weber, M. A., …, & RADIANCE II Investigators and Collaborators (2023). Endovascular Ultrasound Renal Denervation to Treat Hypertension. JAMA, 329(8), 651. https://doi.org/10.1001/jama.2023.0713
Vancouver
Azizi M, Saxena M, Wang Y, Jenkins JS, Devireddy C, Rader F, et al. Endovascular Ultrasound Renal Denervation to Treat Hypertension. JAMA. 2023;329(8):651. doi:10.1001/jama.2023.0713
BibTeX
@article{Azizi2023,
author = {Azizi, Michel and Saxena, Manish and Wang, Yale and Jenkins, J Stephen and Devireddy, Chandan and Rader, Florian and Fisher, Naomi D L and Schmieder, Roland E and Mahfoud, Felix and Lindsey, Jason and Sanghvi, Kintur and Todoran, Thomas M and Pacella, John and Flack, John and Daemen, Joost and Sharp, Andrew S P and Lurz, Philipp and Bloch, Michael J and Weber, Michael A and Lobo, Melvin D and Basile, Jan and Claude, Lisa and Reeve-Stoffer, Helen and McClure, Candace K and Kirtane, Ajay J and RADIANCE II Investigators and Collaborators, RADIANCE II Investigators and Collaborators},
title = {Endovascular Ultrasound Renal Denervation to Treat Hypertension},
journal = {JAMA},
year = {2023},
volume = {329},
number = {8},
pages = {651},
doi = {10.1001/jama.2023.0713}
}
EUVIMED